Industry Briefs

Make no mistake, the race to develop and manufacture a safe alternative to chlorofluorocarbons (CECs) is a hotly contested one. But fierce competition notwithstanding, the contenders in the race have banded together to shorten one key leg of what promises to be a marathon. Eight CFC producers from around the world—Du Pont, AKZO, Allied-Signal, Atochem, Daikin, ISC Chemicals, Pennwalt, and Solvay and Co—have agreed to share toxicity test information on HCFC-1 41 b, one CFC alternativ


Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Make no mistake, the race to develop and manufacture a safe alternative to chlorofluorocarbons (CECs) is a hotly contested one. But fierce competition notwithstanding, the contenders in the race have banded together to shorten one key leg of what promises to be a marathon. Eight CFC producers from around the world—Du Pont, AKZO, Allied-Signal, Atochem, Daikin, ISC Chemicals, Pennwalt, and Solvay and Co—have agreed to share toxicity test information on HCFC-1 41 b, one CFC alternative. By coordinating the $2 million-to-$3 million research, the companies hope to have results in five years rather than six or seven.

Meanwhile, the eight firms are battling to be the first to develop the processes by which alternatives will be manufactured. But a Du Pont spokesperson admits that the companies are taking a gamble by investigating manufacturing procedures before toxicity testing is completed. If the toxicity tests reveal the alternatives as carcinogenic, much time ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo